News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

Opinion|Videos|October 9, 2024 (Updated: October 9, 2024)

Quantifying Success: Measuring Depth of Treatment Response in MDD

Experts in the management of mood disorders comment on how to assess and quantify treatment response in MDD, focusing on effective measurement strategies to guide clinical decisions

Episodes in this series

EP. 1 Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes

EP. 1 Expert Insights into Navigating MDD Prevalence, Stigma, and Treatment Challenges for Improved Patient Outcomes

EP. 2 Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics

EP. 2 Advancing MDD Treatment: From STAR*D Insights to Precision Medicine and Novel Therapeutics

EP. 3 Commentary on Redefining Depression Management with Updated Treatment Strategies

EP. 3 Commentary on Redefining Depression Management with Updated Treatment Strategies

EP. 4 Navigating Non-Response: A Holistic Approach to Patient Care

EP. 4 Navigating Non-Response: A Holistic Approach to Patient Care

EP. 5 Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

EP. 5 Transforming MDD: A Patient's Journey with Rapid-Acting Therapy

EP. 6 Quantifying Success: Measuring Depth of Treatment Response in MDD

EP. 6 Quantifying Success: Measuring Depth of Treatment Response in MDD

EP. 7 Access Challenges: Bridging Insurance Gaps for MDD Innovations

EP. 7 Access Challenges: Bridging Insurance Gaps for MDD Innovations

EP. 8 Depression Treatment: Expert Guide to Medication Management & Therapeutic Success

EP. 8 Depression Treatment: Expert Guide to Medication Management & Therapeutic Success

EP. 9 From Neuroplasticity to Patient Conversations: Managing Affective Disorders Effectively

EP. 9 From Neuroplasticity to Patient Conversations: Managing Affective Disorders Effectively

EP. 10 Managing Persistent MDD: Case Studies and Treatment Challenges

EP. 10 Managing Persistent MDD: Case Studies and Treatment Challenges

EP. 11 Evaluating Treatment Failure and Symptomatic Remission in MDD

EP. 11 Evaluating Treatment Failure and Symptomatic Remission in MDD

EP. 12 Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution

EP. 12 Exploring Rapid-Acting Therapies in MDD: Pharmacodynamics and Treatment Evolution

EP. 13 Addressing Unsatisfactory Responses in Chronic MDD

EP. 13 Addressing Unsatisfactory Responses in Chronic MDD

EP. 14 Defining and Managing Treatment-Resistant Depression: Efficacy and Real-World Insights

EP. 14 Defining and Managing Treatment-Resistant Depression: Efficacy and Real-World Insights

EP. 15 Optimizing Treatment Response: Insights from Clinical Data and Real-World Experience

EP. 15 Optimizing Treatment Response: Insights from Clinical Data and Real-World Experience

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Experts featured in this series.

Multidisciplinary Approaches to Long-Term Narcolepsy Care

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 22nd 2026

Experts featured in this series.

Optimizing Narcolepsy Treatment Through Polypharmacy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Experts featured in this series.

Assessing DEA Scheduling and Emerging Therapies in Narcolepsy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 15th 2026

Experts featured in this series.

Evaluating Pitolisant and Other Pharmacologic Treatment Options for Narcolepsy

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 8th 2026

Experts featured in this series.

Narcolepsy Treatment Considerations in Pediatric Patients

ByKarl Doghramji, MD, FAASM, DFAPA,Michael Strunc, MD,Ellen Wermter, FNP-BC, DBSM, FAASM,W. Christopher Winter, MD

April 8th 2026

Latest CME

Southern California Psychiatry Conference

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Trending on Psychiatric Times

New 6-Month Data From Second Phase 3 Trial Confirms Rapid Effect of COMP360 for TRD

Take-Home Messages: Clinical Confidence in Transitioning Patients to Cobenfy

Phase 2 Trial Initiated for Briumvi for Treatment-Resistant Schizophrenia

Developments in Cannabis Withdrawal and Addiction Treatment

Treating Cannabis Addiction and Withdrawal: Latest Clinical Data